Health Law Institute, Law Centre, University of Alberta, Edmonton, T6G 2H5, Canada.
BMC Med Ethics. 2010 Mar 23;11:4. doi: 10.1186/1472-6939-11-4.
Research involving minors has been the subject of much ethical debate. The growing number of longitudinal, pediatric studies that involve genetic research present even more complex challenges to ensure appropriate protection of children and families as research participants. Long-term studies with a genetic component involve collection, retention and use of biological samples and personal information over many years. Cohort studies may be established to study specific conditions (e.g. autism, asthma) or may have a broad aim to research a range of factors that influence the health and development of children. Studies are increasingly intended to serve as research platforms by providing access to data and biological samples to researchers over many years.This study examines how six birth cohort studies in North America and Europe that involve genetic research handle key ethical, legal and social (ELS) issues: recruitment, especially parental authority to include a child in research; initial parental consent and subsequent assent and/or consent from the maturing child; withdrawal; confidentiality and sample/data protection; handling sensitive information; and disclosure of results.
Semi-structured telephone interviews were carried out in 2008/09 with investigators involved in six birth cohort studies in Canada, Denmark, England, France, the Netherlands and the United States. Interviewees self-identified as being knowledgeable about ELS aspects of the study. Interviews were conducted in English.
The studies vary in breadth of initial consent, but none adopt a blanket consent for future use of samples/data. Ethics review of new studies is a common requirement. Studies that follow children past early childhood recognise a need to seek assent/consent as the child matures. All studies limit access to identifiable data and advise participants of the right to withdraw. The clearest differences among studies concern handling of sensitive information and return of results. In all studies, signs of child abuse require reports to authorities, but this disclosure duty is not always stated in consent materials. Studies vary in whether they will return to participants results of routine tests/measures, but none inform participants about findings with unknown clinical significance.
Analysis of how cohort studies in various jurisdictions handle key ELS issues provides informative data for comparison and contrast. Consideration of these and other examples and further scholarly exploration of ELS issues provides insight on how best to address these aspects in ways that respect the well-being of participants, especially children who become research subjects at the start of their lives.
涉及未成年人的研究一直是伦理辩论的主题。越来越多的涉及遗传研究的纵向儿科研究对确保适当保护儿童和家庭作为研究参与者提出了更复杂的挑战。具有遗传成分的长期研究涉及多年来收集、保留和使用生物样本和个人信息。队列研究可以建立来研究特定的疾病(例如自闭症、哮喘),也可以广泛研究影响儿童健康和发展的一系列因素。这些研究越来越多地旨在成为研究平台,多年来为研究人员提供数据和生物样本的访问权限。本研究考察了北美和欧洲的六项涉及遗传研究的出生队列研究如何处理关键的伦理、法律和社会(ELS)问题:招募,特别是父母授权将孩子纳入研究;最初的父母同意以及随后成熟孩子的同意/同意;退出;保密性和样本/数据保护;处理敏感信息;以及结果披露。
2008/09 年,对加拿大、丹麦、英国、法国、荷兰和美国的六项出生队列研究的调查人员进行了半结构化电话访谈。受访者自认为对研究的 ELS 方面有了解。访谈以英语进行。
这些研究在初始同意的范围上有所不同,但没有一项研究采用通用的样本/数据未来使用同意。新研究的伦理审查是一项常见要求。那些在儿童早期之后跟踪儿童的研究认识到需要在孩子成熟时寻求同意/同意。所有研究都限制对可识别数据的访问,并告知参与者有权退出。研究之间最明显的差异在于处理敏感信息和结果返回。在所有研究中,虐待儿童的迹象都需要向当局报告,但这一披露义务并不总是在同意材料中说明。研究在是否会向参与者返回常规测试/测量的结果方面存在差异,但没有一项研究向参与者告知具有未知临床意义的发现。
分析不同司法管辖区的队列研究如何处理关键的 ELS 问题为比较和对比提供了有信息性的数据。考虑这些以及其他例子,并进一步深入研究 ELS 问题,为以尊重参与者,特别是在生命开始时成为研究对象的儿童的福祉的方式处理这些方面提供了见解。